{'52WeekChange': -0.36700177,
 'SandP52WeekChange': 0.0644362,
 'address1': '950 Winter Street',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 14.72,
 'askSize': 800,
 'averageDailyVolume10Day': 772175,
 'averageVolume': 614152,
 'averageVolume10days': 772175,
 'beta': 1.186554,
 'beta3Year': None,
 'bid': 13.55,
 'bidSize': 1300,
 'bookValue': -1.599,
 'category': None,
 'circulatingSupply': None,
 'city': 'Waltham',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 14.21,
 'dayLow': 13.26,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -6.951,
 'enterpriseToRevenue': 3.77,
 'enterpriseValue': 721632448,
 'exDividendDate': None,
 'exchange': 'NGM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fax': '617 551 4701',
 'fiftyDayAverage': 13.459857,
 'fiftyTwoWeekHigh': 29.97,
 'fiftyTwoWeekLow': 10.32,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 46283322,
 'forwardEps': -1.71,
 'forwardPE': -8.099415,
 'fromCurrency': None,
 'fullTimeEmployees': 383,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.00374,
 'heldPercentInstitutions': 1.12666,
 'industry': 'Drug Manufacturers—Specialty & Generic',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': 1398297600,
 'lastSplitFactor': '1:2',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/radiuspharm.com',
 'longBusinessSummary': 'Radius Health, Inc., a biopharmaceutical company, '
                        'develops and commercializes endocrine therapeutics in '
                        'the areas of osteoporosis and oncology. The company '
                        'markets TYMLOS, an anabolic agent for the treatment '
                        'of postmenopausal women with osteoporosis. It is also '
                        'developing abaloparatide-SC, which is in phase 3 '
                        'clinical study for the treatment of osteoporosis in '
                        'men; abaloparatide transdermal patch, a '
                        'short-wear-time patch, that is in phase 3 clinical '
                        'study to treat postmenopausal women with '
                        'osteoporosis; Elacestrant (RAD1901), a selective '
                        'estrogen receptor degrader, which is in phase 3 '
                        'clinical study for the treatment of hormone '
                        'receptor-positive breast cancer; and RAD140, a '
                        'non-steroidal selective androgen receptor modulator, '
                        'which is in phase 1A clinical study to treat '
                        'metastatic breast cancer. The company has '
                        'collaborations and license agreements with 3M '
                        'Company; Ipsen Pharma SAS; Eisai Co. Ltd.; Duke '
                        'University; and Teijin Limited. Radius Health, Inc. '
                        'was founded in 2003 and is headquartered in Waltham, '
                        'Massachusetts.',
 'longName': 'Radius Health, Inc.',
 'market': 'us_market',
 'marketCap': 642482112,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_9913586',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -127887000,
 'nextFiscalYearEnd': 1640908800,
 'open': 14,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': -0.16,
 'phone': '617 551 4000',
 'previousClose': 12.71,
 'priceHint': 2,
 'priceToBook': None,
 'priceToSalesTrailing12Months': 3.356821,
 'profitMargins': -0.66818,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 14.21,
 'regularMarketDayLow': 13.26,
 'regularMarketOpen': 14,
 'regularMarketPreviousClose': 12.71,
 'regularMarketPrice': 14,
 'regularMarketVolume': 1902598,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 46388600,
 'sharesPercentSharesOut': 0.14130001,
 'sharesShort': 6555961,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 6326884,
 'shortName': 'Radius Health, Inc.',
 'shortPercentOfFloat': 0.19520001,
 'shortRatio': 13.38,
 'startDate': None,
 'state': 'MA',
 'strikePrice': None,
 'symbol': 'RDUS',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -2.77,
 'twoHundredDayAverage': 15.402949,
 'volume': 1902598,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.radiuspharm.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '02451'}